The latest announcement is out from Septerna, Inc. ( (SEPN) ).

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed.

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic collaborations, despite challenges in the US market.

Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

Under the agreement, Novo Nordisk will pay more than $200 million up front, with Septerna eligible to receive up to $2.2 billion based on development.

Cash Position: Cash, cash equivalents, and marketable securities totaled $379.2 million as of June 30, 2025. Following receipt of the $195.0 million upfront payment from Novo Nordisk in July, Septerna ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, T2D and other cardiometabolic diseases.